AI Article Synopsis
- This study focused on the long-term survival rates of biologic drugs in psoriasis patients, highlighting the importance of treatment adherence as a measure of success.
- Adalimumab, efalizumab, etanercept, infliximab, and ustekinumab were analyzed in 125 treatment periods, revealing that patients with psoriatic arthritis and without comorbidities had better drug survival rates.
- The findings suggest that biologic treatments become less effective over time, especially in patients with metabolic syndrome, who tend to be less adherent to their treatment plans.
Article Abstract
Background: Psoriasis often requires lifelong therapy, and adherence to treatment is considered a marker for treatment success. Data on the drug survival of biologics in psoriasis patients with comorbidities are lacking.
Objectives: This study was designed to estimate the long-term drug survival rates of different biologic agents in a cohort of psoriasis patients and to evaluate reasons and predictors for treatment adherence.
Methods: Drug survival rates and outcome parameters in psoriasis patients treated with biologic agents were analyzed.
Results: A total of 125 treatment periods with adalimumab (n = 37), efalizumab (n = 9), etanercept (n = 55), infliximab (n = 13), and ustekinumab (n = 11) were administered to 67 psoriasis patients. Patients with psoriatic arthritis (P = 0.010) and without comorbidity (P = 0.033) demonstrated significantly greater rates of drug survival.
Conclusions: The overall efficacy of biologic agents is reduced with time. Patients with the comorbidity of metabolic syndrome demonstrate a loss of adherence to biologic treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.12879 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.
JCO Glob Oncol
January 2025
Genitourinary Medical Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo, São Paulo, Brazil.
Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.
Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.
Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer.
PLoS One
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Colon cancer, as a highly prevalent malignant tumor globally, poses a significant threat to human health. In recent years, ferroptosis and cuproptosis, as two novel forms of cell death, have attracted widespread attention for their potential roles in the development and treatment of colon cancer. However, the investigation into the subtypes and their impact on the survival of colon cancer patients remains understudied.
View Article and Find Full Text PDFIn vitro cytotoxicity (irritant potency) of toothpaste ingredients.
PLoS One
January 2025
Department of Dental Materials Science, Academic Center for Dentistry (ACTA), University of Amsterdam, Amsterdam, The Netherlands.
Purpose: This study aimed to determine the cytotoxicity (irritant potency) of toothpaste ingredients, of which some had known to have sensitizing properties.
Materials: From the wide variety of toothpaste ingredients, Xylitol, Propylene glycol (PEG), Sodium metaphosphate (SMP), Lemon, Peppermint, Fluoride, Cinnamon, and Triclosan and Sodium dodecyl sulphate (SDS) have been selected for evaluation of their cytotoxic properties.
Methods: Reconstructed human gingiva (RHG) were topically exposed to toothpaste ingredients at different concentrations.
Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate.
Eur J Endocrinol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Objective: Rebound vertebral fractures (VFs) after Denosumab (Dmab) withdrawal have been documented, highlighting the need for further research into this phenomenon and the importance of a well-planned strategy for discontinuing Dmab.
Methods: From the TriNetX US network, we enrolled osteoporosis patients aged 50 years or older who had withdrawn from at least two doses of Dmab and compared them with a matched cohort who had received at least one dose of zoledronate (ZOL) before discontinuation. We analyzed hazard ratios (HR) with 95% confidence intervals (CI) and conducted Kaplan-Meier analyses, along with subgroup analyses, drug discontinuation modification, and sensitivity analyses.
Chitosan-Functionalized Fluorescent Calcium Carbonate Nanoparticle Loaded with Methotrexate: Future Theranostics for Triple Negative Breast Cancer.
ACS Biomater Sci Eng
January 2025
Nano 2 Micro Material Design Lab, Department of Chemical Engineering and Technology, IIT (BHU), Varanasi 221005, India.
Herein, fluorescent calcium carbonate nanoclusters encapsulated with methotrexate (Mtx) and surface functionalized with chitosan (25 nm) (@Calmat) have been developed for the imaging and treatment of triple-negative breast cancer (TNBC). These biocompatible, pH-sensitive nanoparticles demonstrate significant potential for targeted therapy and diagnostic applications. The efficacy of nanoparticles (NPs) was evaluated in MDA-MB-231 TNBC cell lines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!